Ayesha Alvero

Ayesha Alvero

Professor, Research

Ayesha Alvero


Dr. Alvero is a Cancer Biologist with research focus in ovarian cancer. Her work unraveled specific molecular mechanisms that allow cancer stems cells to evade apoptosis and develop chemoresistance. Dr. Alvero identified targetable alternative cell death pathways that can circumvent apoptosis in chemoresistant cancer cells leading to the generation of robust proof-of-concept studies supporting clinical trials for Phenoxodiol, a chemosensitizer; NV-128/ME-344, an isoflavone derived mitochondrial inhibitor; and Cantrixil, a potent and selective cytotoxic super-benzopyran.

Dr. Alvero received her research training and was a faculty at the Department of Obstetrics, Gynecology, and Reproductive Sciences at Yale University School of Medicine before joining the C.S. Mott Center. Her present research continues to identify targetable molecular mechanisms that can prevent ovarian cancer recurrence with current focus on mechanisms of resistance to immunotherapies and the contribution of the tumor microenvironment in sustaining recurrent disease. Her more recent publication showcased the value of dendritic cell-based vaccination and oncoimmuno-modulatory virus-like vesicles in the prevention of recurrent ovarian cancer.


Links of Interest





 Representative recent publications

1. You Y, Grasso E, Alvero A, Condon J, Dimova T, Hu A, Ding J, Alexandrova M, Manchorova D, Dimitrova V, Liao A, Mor G. Twist1-IRF9 Interaction Is Necessary for IFN-Stimulated Gene Anti-Zika Viral Infection. J Immunol. 2023 May 5:ji2300081. doi: 10.4049/jimmunol.2300081.

2. CARG-2020 SGO

3. Tedja R, Alvero AB, Fox A, Cardenas C, Pitruzzello M, Chehade H, Bawa T, Adzibolosu N, Gogoi R, Mor G. Generation of Stable Epithelial-Mesenchymal Hybrid Cancer Cells with Tumorigenic Potential. Cancers (Basel). 2023 Jan 22;15(3):684. doi: 10.3390/ cancers15030684.

4. Chehade H, Purandare N, Fox A, Adzibolosu N, Jayee S, Singh A, Tedja R, Gogoi R, Aras S, Grossman LI, Mor G, Alvero AB. MNRR1 is a driver of ovarian cancer progression.
Transl Oncol. 2023 Mar;29:101623. doi: 10.1016/j.tranon.2023.101623.

5. Liu J, Shu G, Wu A, Zhang X, Zhou Z, Alvero AB, Mor G, Yin G. TWIST1 induces proteasomal degradation of β-catenin during the differentiation of ovarian cancer stem-like cells.
Sci Rep. 2022 Sep 19;12(1):15650. doi: 10.1038/s41598-022-18662-2.

6. Chehade H, Tedja R, Ramos H, Bawa TS, Adzibolosu N, Gogoi R, Mor G, Alvero AB Chehade H, Tedja R, Ramos H, Bawa TS, Adzibolosu N, Gogoi R, Mor G, Alvero AB. Regulatory Role of the Adipose Microenvironment on Ovarian Cancer Progression.
Cancers (Basel). 2022 May 1;14(9):2267. doi: 10.3390/cancers14092267.

7. Udumula MP, Sakr S, Dar S, Alvero AB, Ali-Fehmi R, Abdulfatah E, Li J, Jiang J, Tang A, Buekers T, Morris R, Munkarah A, Giri S, Rattan R. Ovarian cancer modulates the immunosuppressive function of CD11b+Gr1+ myeloid cells via glutamine metabolism. Mol Metab. 2021 Nov;53:101272. doi: 10.1016/j.molmet.2021.101272.

8. van den Pol AN, Zhang X, Lima E, Pitruzzello M, Albayrak N, Alvero A, Davis JN, Mor G. Lassa-VSV chimeric virus targets and destroys human and mouse ovarian cancer by direct oncolytic action and by initiating an anti-tumor response. Virology. 2021 Mar;555:44-55. doi: 10.1016/j.virol.2020.10.009.

9. Alvero AB, Hanlon D, Pitruzzello M, Filler R, Robinson E, Sobolev O, Tedja R, Ventura A, Bosenberg M, Han P, Edelson RL, Mor G. Transimmunization restores immune surveillance and prevents recurrence in a syngeneic mouse model of ovarian cancer. Oncoimmunology. 2020 May 13;9(1):1758869. doi: 10.1080/2162402X.2020.1758869.

Other Information


Co-Inventor US20170281588
Compositions and Methods for Treating Epithelial Cancer

Co-Inventor EP2953938A1
Functionalised benzopyran compounds and use thereof

Co-Inventor US2012251630
Remission therapy of cancer with isoflavonoids


← Return to listing